Novo Nordisk's long-acting insulin Tresiba is set to gain new hypoglycaemia prevention claims in Europe, giving it an advantage over Sanofi’s top-selling Lantus. Europe's CHMP committee has just ...
Novo Nordisk presented the latest results for its diabetes injectable Tresiba last weekend. These demonstrated significantly better control of blood sugar levels than Sanofi’s Toujeo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback